Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.21 (
CPT
)
4,580
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lipid storage myopathies (LSMs) are characterized pathologically by the accumulation of lipid droplets in muscle fibers due to impaired cellular lipid metabolism. The purpose of this study was to determine etiologies and genetic mutations associated with LSMs in ethnic Han Taiwanese. The usefulness of the blood acylcarnitine (AC) profile for diagnosing LSMs in adult patients was also investigated. Nine patients were diagnosed with late-onset LSMs following a review of muscle biopsies and medical records and were recruited retrospectively. Genetic studies were performed to detect mutations in the SLC22A5 for primary carnitine deficiency, PNPLA2 for neutral lipid storage disease with myopathy, ABHD5 for neutral lipid storage disease with ichthyosis,
ETFDH
for multiple acyl-CoA dehydrogenation deficiency (MADD), and CPT2 for
carnitine palmitoyltransferase II
deficiency. Blood AC levels were measured by tandem mass spectrometry. The mutation c.250G>A in
ETFDH
was detected in seven (78%) patients, six of whom were homozygous for the variant. Patients with
ETFDH
mutations had elevated blood levels of ACs ranging from C8 to C16 species, a pattern consistent with MADD.
ETFDH
c.250G>A mutation is common in Taiwanese patients with late-onset LSMs. The blood AC profile is a sensitive biochemical marker for diagnosing MADD arising from
ETFDH
mutations in adults.
...
PMID:High frequency of ETFDH c.250G>A mutation in Taiwanese patients with late-onset lipid storage myopathy. 2037 Jul 97